How many drugs treat Decompensated cardiac failure?

Drug Landscape tracks 9 marketed treatments for Decompensated cardiac failure (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/decompensated-cardiac-failure.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Decompensated cardiac failure — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Decompensated cardiac failure (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Decompensated cardiac failure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Natrecor	NESIRITIDE	Scios Llc	Natriuretic Peptide	Atrial natriuretic peptide receptor 1	2001-01-01
Primacor	MILRINONE	Sanofi	Phosphodiesterase 3 Inhibitor	Phosphodiesterase 3	1987-01-01
Cartonic	amrinone	Sanofi	amrinone	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	1984-01-01
Dobutamine Hydrochloride In Dextrose 5% In Plastic Container	Dobutamine Hydrochloride	Pfizer Inc.	Inotropic agent	Beta-receptors of the heart	1978-01-01
Sodium Nitroprusside	NITROPRUSSIDE	Roche	Vasodilator	Atrial natriuretic peptide receptor 1	1974-01-01
Lasix	furosemide	Generic (originally Hoechst AG)	Loop Diuretic [EPC]	ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35	1966-07-01
Torasemide	Torasemide	Medical University of Warsaw		Solute carrier family 12 member 1
Frusemide	Frusemide	Melbourne Health		ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35
Dobutamin	Dobutamin	Competence Network for Congenital Heart Defects		Solute carrier family 22 member 1, Alpha-1D adrenergic receptor, Alpha-2B adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Sanofi · 2 drugs in Decompensated cardiac failure
· 2 drugs in Decompensated cardiac failure
Generic (originally Hoechst AG) · 1 drug in Decompensated cardiac failure
Medical University of Warsaw · 1 drug in Decompensated cardiac failure
Melbourne Health · 1 drug in Decompensated cardiac failure
Pfizer Inc. · 1 drug in Decompensated cardiac failure
Roche · 1 drug in Decompensated cardiac failure
Scios Llc · 1 drug in Decompensated cardiac failure
Competence Network for Congenital Heart Defects · 1 drug in Decompensated cardiac failure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Decompensated cardiac failure:

Cite this brief

Drug Landscape (2026). Decompensated cardiac failure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/decompensated-cardiac-failure. Accessed 2026-06-10.

Decompensated cardiac failure full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing